Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jun;45(6):1621-8.
doi: 10.1128/AAC.45.6.1621-1628.2001.

Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance

J L Hammond  1 , D L Koontz, H Z Bazmi, J R Beadle, S E Hostetler, G D Kini, K A Aldern, D D Richman, K Y Hostetler, J W Mellors
Affiliations

Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance

J L Hammond et al. Antimicrob Agents Chemother. 2001 Jun.

Abstract

Phosphonoformate (foscarnet; PFA) is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), but its use for the treatment of HIV-1 infection is limited by toxicity and the lack of an orally bioavailable formulation. Alkylglycerol-conjugated prodrugs of PFA (1-O-octadecyl-sn-glycero-3-PFA [B-PFA]) having sn-2 substituents of hydrogen (deoxybatyl-PFA [DB-PFA]), methyl (MB-PFA), or ethyl (EB-PFA) are more-potent inhibitors of wild-type HIV-1 in vitro than unmodified PFA and are orally bioavailable in mice. We have evaluated the activities of these compounds against a panel of nucleoside-resistant HIV-1 variants and have characterized the resistant variants that emerge following in vitro selection with the prodrugs. Except for an HIV-1 variant encoding the K65R mutation in RT that exhibited 3.3- to 8.2-fold resistance, the nucleoside-resistant viruses included in the panel were sensitive to the PFA prodrugs (<3-fold increase in 50% inhibitory concentration), including multinucleoside-resistant variants encoding the Q151M complex of mutations or the T69S[SA] insert. Viruses resistant to the PFA prodrugs (>10-fold) were selected in vitro after 15 or more serial passages of HIV-1 in MT-2 cells in escalating prodrug concentrations. Mutations detected in the resistant viruses were S117T, F160Y, and L214F (DB-PFA); M164I and L214F (MB-PFA); and W88G and L214F (EB-PFA). The S117T, F160Y, and M164I mutations have not been previously identified. Generation of recombinant viruses encoding the single and double mutations confirmed their roles in prodrug resistance, including 214F, which generally increased the level of resistance. When introduced into a zidovudine (AZT)-resistant background (67N 70R 215F 219Q), the W88G, S117T, F160Y, and M164I mutations reversed AZT resistance. This suppression of AZT resistance is consistent with the effects of other foscarnet resistance mutations that reduce ATP-dependent removal of AZT monophosphate from terminated template primers. The favorable activity and resistance profiles of these PFA prodrugs warrant their further evaluation as clinical candidates.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Alkylglycerol PFA prodrug structures.
See this image and copyright information in PMC

References

    1. Arion D, Kaushik N, McCormick S, Borkow G, Parniak M A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry. 1998;37:15908–15917. - PubMed
    1. Arion D, Sluis-Cremer N, Parniak M A. Mechanism by which phosphonoformic acid resistance mutations restore 3′-azido-3′-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. J Biol Chem. 2000;275:9251–9255. - PubMed
    1. Bacigalup A, vanLint M T, Tedone E, Moro F, Sanna M A, Longren M, Trespi G, Frassoni F, Occhini D, Gualandi F. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant. 1994;13:753–758. - PubMed
    1. Bazmi H Z, Hammond J L, Calvalcanti S C H, Chu C K, Schinazi R F, Mellors J W. In vitro selection of mutations in HIV-1 reverse transcriptase that decrease susceptibility to (−)-β-d-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 2000;44:1783–1788. - PMC - PubMed
    1. Beadle J R, Kini G D, Aldern K A, Gardner M F, Wright K N, Richman D D, Hostetler K Y. Alkylthioglycerol prodrugs of foascarnet: synthesis, oral bioavailability, and structure-activity studies in human cytomegalovirus, herpes simplex virus type 1 and human immunodeficiency virus type 1 infected cells. Antivir Chem Chemother. 1998;9:33–40. - PubMed

Publication types

MeSH terms

LinkOut - more resources